DOI: 10.1055/s-00000030

Der Klinikarzt

References

Martin M, Holmes FA, Ejlertsen B. et al.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet Oncol 2017;
18: 1688-1700

Download Bibliographical Data

Search in:
Access:
Access: